Norovirus Vaccine Trial Fails Interim Bar; Moderna Lifts 2026 Outlook
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna's Phase 3 norovirus vaccine trial missed the interim criteria for early success, and the company will not enroll another cohort this season while it consults health officials on next steps. That is the negative offset in an otherwise strong update: Q3 revenue rose 29% to $1.313 billion with $162 million of net income versus a year-earlier loss, and management raised 2026 revenue growth guidance to 15%-25%. The mFLUSIVA flu vaccine is now approved and the melanoma program posted positive Phase 3 results, extending the pipeline story that drove the stock's August run. The norovirus setback removes a near-term catalyst from a company trading near its 52-week high, so the market has to weigh a profitable core against a pipeline hole. Next checkpoint is the company's consultation with health officials on the norovirus path forward.
At the time of this announcement, MRNA was trading at $256.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.5B. The 52-week trading range was $22.28 to $267.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.